Calidi Biotherapeutics Stock Price, News & Analysis

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology and biotechnology company focused on the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. According to the company’s public disclosures, Calidi is advancing systemically delivered, oncolytic virus-based genetic medicines aimed at metastatic cancer and other tumor types with high unmet medical need.

Calidi’s work is centered on its proprietary RedTail platform, which the company describes as an engineered, enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This enveloped viral technology is intended to shield the virus from immune clearance, allowing virotherapy to circulate in the body, reach tumor sites, induce tumor lysis, and deliver potent gene therapies or genetic medicines directly within the tumor microenvironment.

RedTail platform and mechanism

The RedTail platform utilizes an enveloped form of vaccinia virus that has been genetically engineered to avoid immune detection and support systemic administration. Company materials state that this design is intended to:

• Protect the virus from immune clearance after systemic dosing
• Enable tropism for metastatic tumor sites
• Replicate specifically in tumor cells
• Induce an immune priming event at the tumor site
• Express high levels of therapeutic genetic payloads in the tumor microenvironment

Calidi has reported preclinical data in syngeneic murine models showing that the RedTail platform can remain protected from immune clearance following systemic administration, locate and replicate in tumor cells at metastatic sites, and express genetic medicines at the tumor site at levels similar to those achieved with localized dosing, while limiting systemic exposure.

Lead program: CLD-401

The company’s lead therapeutic candidate from the RedTail platform is CLD-401. Calidi describes CLD-401 as a tumor-tropic oncolytic virus designed to home to metastatic sites after systemic administration, replicate only in tumor cells, induce an immune priming event at the tumor site, and express high levels of an IL-15 superagonist in the tumor microenvironment. IL-15 superagonist is characterized by the company as a potent cytokine that induces natural killer (NK) cell and T-cell responses against tumors.

According to multiple company press releases, CLD-401 is in IND-enabling studies and is intended to target non-small cell lung cancer, head and neck cancer, ovarian cancer, and other tumor types with high unmet medical need. Calidi has highlighted preclinical data presented at the Society for Immunotherapy of Cancer (SITC) annual meeting, where CLD-401 and the RedTail platform were reported to:

• Remain protected from immune clearance after systemic administration in syngeneic murine models
• Find and specifically replicate in tumor cells at metastatic sites
• Deliver IL-15 superagonist and other genetic medicines at the tumor site at concentrations comparable to localized dosing, while limiting systemic exposure

The company has also described CLD-401 as part of a broader effort to advance systemically delivered, targeted genetic medicines and has discussed pursuing strategic partnerships to support clinical development of this program and the underlying platform.

Additional virotherapy programs

In addition to CLD-401 and the RedTail platform, Calidi reports that it is developing protected virotherapies for intratumoral and localized administration. These clinical-stage programs are described as focusing on a subset of injectable cancer indications. Public descriptions also reference earlier pipeline designations such as CLD-101 for recurrent high-grade gliomas, CLD-201 for solid tumors, CLD-400 for certain lung cancer and metastatic solid tumors, and discovery research on CLD-301 for tumor indications, reflecting the company’s broader interest in oncolytic virus and stem cell-based approaches.

Corporate profile and listing

Calidi Biotherapeutics is headquartered in San Diego, California. The company’s common stock trades on the NYSE American exchange under the ticker symbol CLDI, as reflected in its SEC filings and repeated in its press releases. Calidi identifies itself as operating in the biotechnology and immuno-oncology space, with a focus on research and development of genetic medicine platforms and therapeutic candidates.

Research, collaborations, and advisory expertise

Calidi’s public communications emphasize ongoing preclinical research, IND-enabling work, and participation in scientific and investor conferences. The company has presented data on CLD-401 and the RedTail platform at the SITC Annual Meeting and has held investor-focused events around these presentations.

Calidi has also announced the establishment of a Scientific Advisory Board (SAB) composed of academic and industry experts in cancer immunotherapy, virotherapy, and IL-15-based treatments. According to company disclosures, the SAB is intended to support the development of CLD-401 and guide the evolution of the RedTail platform for systemic delivery of targeted genetic medicine.

In addition, Calidi has disclosed a partnership with Matica Biotechnology, Inc., a viral vector contract development and manufacturing organization (CDMO). Under this agreement, Matica Bio is providing analytical development, process development, and GMP manufacturing services to support the IND submission for CLD-401, reinforcing Calidi’s focus on moving its lead program toward clinical evaluation.

Capital markets and financing activity

Calidi’s SEC filings and press releases describe capital-raising activities, including an underwritten public offering of common stock units and pre-funded warrant units. The company has indicated that proceeds from such offerings are intended for working capital, general corporate purposes, and preclinical and clinical trial preparation. These disclosures, along with periodic financial reports filed with the SEC, outline Calidi’s efforts to fund its research and development programs and corporate operations.

Regulatory and development stage

Across its public statements, Calidi consistently characterizes itself as a clinical-stage company. The RedTail platform’s lead candidate, CLD-401, is described as being in IND-enabling studies, with the company indicating plans to submit an Investigational New Drug (IND) application by a specified future time frame. Additional protected virotherapy programs are described as being in clinical-stage development for intratumoral and localized administration in injectable cancer indications.

Business focus within biotechnology

Within the broader biotechnology sector, Calidi’s stated focus is on immuno-oncology and genetic medicines that use oncolytic viruses as delivery vehicles. The company’s disclosures emphasize:

• Systemic administration of enveloped oncolytic viruses designed to evade immune clearance
• Targeting of metastatic tumor sites
• Induction of tumor lysis and immune priming within the tumor microenvironment
• Delivery of potent genetic payloads, such as IL-15 superagonist, at the tumor site

This focus aligns with Calidi’s classification under research and development in biotechnology and professional, scientific, and technical services.

Use of SEC filings and public information

Investors and researchers can follow Calidi Biotherapeutics through its NYSE American listing under the symbol CLDI and through its periodic and current reports filed with the U.S. Securities and Exchange Commission. These filings, including Forms 10-K, 10-Q, 8-K, and registration statements such as Form S-1, provide additional detail on the company’s risk factors, financial condition, capital structure, and development plans.